Cargando…
Targeted treatments for cervical cancer: a review
Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%–95% of women with early stage cancer, the recurrent and metastat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493318/ https://www.ncbi.nlm.nih.gov/pubmed/23144564 http://dx.doi.org/10.2147/OTT.S25123 |
_version_ | 1782249241637289984 |
---|---|
author | Peralta-Zaragoza, Oscar Bermúdez-Morales, Víctor Hugo Pérez-Plasencia, Carlos Salazar-León, Jonathan Gómez-Cerón, Claudia Madrid-Marina, Vicente |
author_facet | Peralta-Zaragoza, Oscar Bermúdez-Morales, Víctor Hugo Pérez-Plasencia, Carlos Salazar-León, Jonathan Gómez-Cerón, Claudia Madrid-Marina, Vicente |
author_sort | Peralta-Zaragoza, Oscar |
collection | PubMed |
description | Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%–95% of women with early stage cancer, the recurrent and metastatic disease remains a major cause of cancer death. Many efforts have been made to design new drugs and develop gene therapies to treat cervical cancer. In recent decades, research on treatment strategies has proposed several options, including the role of HPV E6 and E7 oncogenes, which are retained and expressed in most cervical cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype. Other efforts have been focused on antitumor immunotherapy strategies. It is known that during the development of cervical cancer, a cascade of abnormal events is induced, including disruption of cellular cycle control, perturbation of antitumor immune response, alteration of gene expression, and deregulation of microRNA expression. Thus, in this review article we discuss potential targets for the treatment of cervical cancer associated with HPV infection, with special attention to immunotherapy approaches, clinical trials, siRNA molecules, and their implications as gene therapy strategies against cervical cancer development. |
format | Online Article Text |
id | pubmed-3493318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-34933182012-11-09 Targeted treatments for cervical cancer: a review Peralta-Zaragoza, Oscar Bermúdez-Morales, Víctor Hugo Pérez-Plasencia, Carlos Salazar-León, Jonathan Gómez-Cerón, Claudia Madrid-Marina, Vicente Onco Targets Ther Review Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%–95% of women with early stage cancer, the recurrent and metastatic disease remains a major cause of cancer death. Many efforts have been made to design new drugs and develop gene therapies to treat cervical cancer. In recent decades, research on treatment strategies has proposed several options, including the role of HPV E6 and E7 oncogenes, which are retained and expressed in most cervical cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype. Other efforts have been focused on antitumor immunotherapy strategies. It is known that during the development of cervical cancer, a cascade of abnormal events is induced, including disruption of cellular cycle control, perturbation of antitumor immune response, alteration of gene expression, and deregulation of microRNA expression. Thus, in this review article we discuss potential targets for the treatment of cervical cancer associated with HPV infection, with special attention to immunotherapy approaches, clinical trials, siRNA molecules, and their implications as gene therapy strategies against cervical cancer development. Dove Medical Press 2012-11-02 /pmc/articles/PMC3493318/ /pubmed/23144564 http://dx.doi.org/10.2147/OTT.S25123 Text en © 2012 Peralta-Zaragoza et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Peralta-Zaragoza, Oscar Bermúdez-Morales, Víctor Hugo Pérez-Plasencia, Carlos Salazar-León, Jonathan Gómez-Cerón, Claudia Madrid-Marina, Vicente Targeted treatments for cervical cancer: a review |
title | Targeted treatments for cervical cancer: a review |
title_full | Targeted treatments for cervical cancer: a review |
title_fullStr | Targeted treatments for cervical cancer: a review |
title_full_unstemmed | Targeted treatments for cervical cancer: a review |
title_short | Targeted treatments for cervical cancer: a review |
title_sort | targeted treatments for cervical cancer: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493318/ https://www.ncbi.nlm.nih.gov/pubmed/23144564 http://dx.doi.org/10.2147/OTT.S25123 |
work_keys_str_mv | AT peraltazaragozaoscar targetedtreatmentsforcervicalcancerareview AT bermudezmoralesvictorhugo targetedtreatmentsforcervicalcancerareview AT perezplasenciacarlos targetedtreatmentsforcervicalcancerareview AT salazarleonjonathan targetedtreatmentsforcervicalcancerareview AT gomezceronclaudia targetedtreatmentsforcervicalcancerareview AT madridmarinavicente targetedtreatmentsforcervicalcancerareview |